Journal article
Determinants of durable humoral and T cell immunity in myeloma patients following COVID-19 vaccination
- Abstract:
-
Objective: To describe determinants of persisting humoral and cellular immune response to the second COVID-19 vaccination among patients with myeloma.
Methods: This is a prospective, observational study utilising the RUDYstudy.org platform. Participants reported their second and third COVID-19 vaccination dates. Myeloma patients had an Anti-S antibody level sample taken at least 21 days after their second vaccination and a repeat sample before their third vaccination.
Results: 60 patients provided samples at least 3 weeks (median 57.5 days) after their second vaccination and before their third vaccination (median 176.0 days after second vaccine dose). Low Anti-S antibody levels (<50 IU/mL) doubled during this interval (p = .023) and, in the 47 participants with T-spot data, there was a 25% increase negative T-spot tests (p = .008). Low anti–S antibody levels prior to the third vaccination were predicted by lower Anti-S antibody level and negative T-spot status after the second vaccine. Independent determinants of a negative T-spot included increasing age, previous COVID infection, high CD4 count and lower percentage change in Anti-S antibody levels.
Conclusions: Negative T-spot results predict low Anti-S antibody levels (<50 IU/mL) following a second COVID-19 vaccination and a number of biomarkers predict T cell responses in myeloma patients.
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Version of record, pdf, 1.5MB, Terms of use)
-
- Publisher copy:
- 10.1111/ejh.14143
Authors
- Publisher:
- Wiley
- Journal:
- European Journal of Haematology More from this journal
- Volume:
- 112
- Issue:
- 4
- Pages:
- 547-553
- Publication date:
- 2023-12-20
- Acceptance date:
- 2023-11-27
- DOI:
- EISSN:
-
1600-0609
- ISSN:
-
0902-4441
- Language:
-
English
- Keywords:
- Pubs id:
-
1585884
- Local pid:
-
pubs:1585884
- Deposit date:
-
2023-12-20
- ARK identifier:
Terms of use
- Copyright holder:
- Twumasi et al.
- Copyright date:
- 2023
- Rights statement:
- © 2023 The Authors. European Journal of Haematology published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
If you are the owner of this record, you can report an update to it here: Report update to this record